All Products
top rated products
Lunan Pharma’s Shenlida®Polyethylene Glycolated Human Granulocyte Stimulating Factor Injection (Biol
Time:2021-05-08 15:58:47 Views:259
New Media Department Yu Jie, Duan Yuqing May 8, 2021
Polyethylene Glycolated Human Granulocyte Stimulating Factor Injection (Specification: 1.0ml:3.0mg) [Approval Number: S20210011] was approved and marketed by the National Medical Products Administration (NMPA) in May 2021.
The mechanism of action of PEG-G-CSF is that granulocyte-stimulating factor binds to the surface receptors of hematopoietic cells to stimulate proliferation and prevent the proliferation of functionally activated cells.
The clinical indications: can reduce the incidence of febrile neutropenia infection in patients with nonmyeloid malignancies who may develop clinically significant febrile neutropenic myelosuppression during antitumor therapy.